Cartilage degradation independent of MMP/aggrecanases  by Sugimoto, Kotaro et al.
Cartilage degradation independent of MMP/aggrecanases
Kotaro Sugimoto M.S.y, Tomoko Iizawa B.S.y, Hosami Harada Ph.D.y, Kazuyo Yamada B.S.z,
Mutsumi Katsumata B.S.z and Masaaki Takahashi Ph.D.y*
y Lead Discovery Research Laboratories, Sankyo Co., Ltd., Tokyo 140-8710, Japan
zBiological Research Laboratories, Sankyo Co., Ltd., Tokyo 140-8710, Japan
Summary
Objective: To identify and characterize a cartilage degradation mechanism that is independent of the proteolytic cleavages by matrix
metalloproteinases (MMPs) and aggrecanases.
Methods: The sensitivity of glycosaminoglycan (GAG) release and collagen release to an MMP/aggrecanase inhibitor, AG3340, was
compared using a bovine nasal cartilage explant culture. The release of matrix proteins and hyaluronan (HA) from the culture was analyzed by
immunoblotting and radioimmunoassay, respectively. Induction of HA-degrading activity by retinoic acid was examined using the cartilage
explant culture and a primary culture of chondrocytes. Degradation of the matrix components of cartilage was also characterized in vivo using
an acute arthritis model induced by an intra-articular injection of interleukin 1a (IL-1a).
Results: AG3340 did not effectively inhibit GAG release at a concentration of more than 10 mM, while 10 nM of the inhibitor completely
suppressed collagen degradation. Retinoic acid induced the release of the aggrecan G1 domain, link protein and HA into the culture medium,
and the release of these molecules was not completely inhibited by 10 mM of AG3340. The molecules were released as ternary complexes.
Retinoic acid induced HA degradation in the explant culture and hyaluronidase activity in the primary culture of chondrocytes. The release of
the G1 domain of aggrecan and link protein into the synovial ﬂuid was also observed in the IL-1a-induced acute arthritis model.
Conclusion: A novel mechanism by chondrocyte-derived hyaluronidase(s) is involved in the release of the matrix components from cartilage,
and the hyaluronidase(s) and MMPs/aggrecanases act in a coordinated manner in cartilage degradation.
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The unique biomechanical properties of articular cartilage
are provided by its extracellular matrix. The extracellular
matrix consists of two major components: the network of
type II collagen, which provides the tensile strength and
stiffness of articular cartilage1, and the large aggregating
proteoglycan, aggrecan, which is responsible for the
osmotic swelling capability, and thus the elasticity, of the
cartilage matrix2,3. Aggrecan consists of an extended
protein core, which can be subdivided into several structure
regions: the N-terminal globular G1 and G2 domains, the
keratan sulfate and chondroitin sulfate attachment region,
and the C-terminal globular G3 domain4. At the G1 domain
of their core proteins, aggrecan monomers are attached to
hyaluronan (HA) and link protein to form large aggregates4.
This aggregate formation is important from the physiological
point of view, since it ensures the retention of aggrecan
within the collagen network and its size is believed to be
responsible for its retention within the cartilage.
The destruction of joint cartilage is the major cause of
human arthritic diseases, i.e., osteoarthritis (OA) and
rheumatoid arthritis (RA). Proteolytic cleavage of the
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2004.100aggrecan core protein within the interglobular domain
(IGD) between the G1 and G2 domains has been reported
to be a key event in the progress of these joint diseases. In
this IGD, two major cleavage sites have been determined
by using anti-neoepitope antibodies recognizing speciﬁc
aggrecan degradation products5, and by their characteriza-
tion by N-terminal protein sequencing6,7. The ﬁrst site
between Glu373 and Ala374 is termed the aggrecanase site,
and is cleaved by aggrecanase-1 (a disintegrin and metal-
loproteinase with thrombospondin motifs (ADAMTS)-4),
aggrecanase-2 (ADAMTS-5) and ADAMTS-18e12. The
second site between Asn341 and Phe342 is termed the
matrix metalloproteinase (MMP) site, and is cleaved by
several members of this protease family13. Cleavage at
these sites causes the release of the glycosaminoglycan
(GAG)-attaching aggrecan backbone from the cartilage
matrix and the resultant G1 domain is thought to remain
attached to the HA backbone of the aggregate4.
A series of potent MMP/aggrecanase inhibitors have
been reported to suppress matrix degradation in cartilage
explant cultures and inhibit the enzymatic activities of
MMPs and aggrecanases in vitro14e19. Although clinical
trials for these inhibitors for prevention of progressive joint
destruction are still under way, there are arguments
regarding their efﬁcacies in vivo, which suggest that
cartilage destruction in joint diseases is not solely attribut-
able to such proteolytic activities20,21.
In this study, we identiﬁed and characterized a novel
mechanism for cartilage degradation using a bovine nasal
cartilage culture system. The mechanism involves HA6
1007Osteoarthritis and Cartilage Vol. 12, No. 12degradation mediated by chondrocytes, and results in the
release of aggrecan, link protein and HA as a ternary
complex from cartilage tissue.
Materials and methods
MATERIALS
A hydroxamate inhibitor, AG3340, was synthesized at the
Medicinal Chemistry Research Laboratories, Sankyo, as
described previously22. HA from cockscomb (1580 kDa),
from the human umbilical cord (800e1200 kDa), and from
pig skin (40e60 kDa) were purchased from Seikagaku
Kogyo (Tokyo, Japan). A polyclonal antiserum, I19C,
speciﬁc to the neoepitope of aggrecan (NITEGE373)
generated from the cleavage at the Glu373eAla374 bond
by aggrecanases was described previously23. An anti-
aggrecan G1 domain mouse monoclonal antibody, F12-1,
was developed against the amino acid sequences
CDAGWLADQTVRYPI (residues 180e194). An anti-link
protein monoclonal antibody, 8A424, was purchased from
American Research Products (Belmont, MA).
PREPARATION OF PROTEASES AND ASSAY
OF THEIR ACTIVITIES
Full-length cDNA encoding human MMP-13 was inserted
into an expression vector, pcDL-SRa29625. Full-length
cDNAs encoding human aggrecanase-1 or aggrecanase-2
were inserted into an expression vector, pcDNA3.1/myc-His
(Invitrogen). The cDNAs were transiently transfected into
COS-1 cells or HEK 293 cells26. After 48 h of transfection,
the culture media were collected and used as enzyme
sources. The expressed MMP-13 was activated by p-
aminophenylmercuric acetate just before use. Enzymatic
activities were determined using a quenched ﬂuorescent
peptide substrate for MMP-1327, or the particle assay for
aggrecanase-1 and aggrecanase-223.
ANALYSIS OF THE MATRIX COMPONENTS IN A
CARTILAGE EXPLANT CULTURE
Bovine nasal cartilage (5 g) was cultured in 30 ml of
serum-free medium [Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) containing 20 mM HEPES, pH 7.3, 100 units/ml
penicillin, 100 mg/ml streptomycin, insulinetransferrinese-
lenium, and 0.03% (w/v) bovine serum albumin (BSA)] for
48 h. For the analysis of collagenolytic activity, 10 ng/ml of
interleukin 1a (IL-1a) (PeproTech, Rocky Hill, NJ) and
50 ng/ml of oncostatin M (Genzyme/Techne, Minneapolis,
MN) were added into the medium, and then the cultures
were maintained with a weekly medium exchange. Hydrox-
yproline in the medium was measured using a colorimetric
assay28. For the analysis on the release of GAG, aggrecan,
link protein and HA, all-trans-retinoic acid (1 mM) was added
to the medium. The cultures were maintained with a daily
medium exchange. GAG concentration in the medium was
determined by dimethylmethylene blue (DMMB) assay
using whale chondroitin sulfate as a standard29. The HA
concentration in the culture medium was quantiﬁed by HA-
test (Pharmacia), which utilizes an iodinated HA binding
protein for detection. Aggrecan or link protein in the medium
was detected by immunoblotting. The collected media
(50 ml) were each treated with 0.15 unit of chondroitinase
ABC (Seikagaku Kogyo) and 0.1 unit of keratanase
(Seikagaku Kogyo) in 20 mM TriseHCl, pH 8.0, 30 mM
sodium acetate, and 10 mM ethylene diamine tetra-aceticacid (EDTA) at 37(C for 30 min. After the deglycosylation,
samples were subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) using 2e15%
or 4e20% gradient gels, transferred to polyvinylidene
diﬂuoride membranes, and probed with I19C, F12-1 or
8A4 antibody.
EVALUATION OF HA DEGRADATION
Extraction of HA from cartilage or medium was performed
as described previously with a slight modiﬁcation23,30,31. In
brief, cartilage was extracted with 10 volumes (w/v) of
extraction buffer (4 M guanidine hydrochloride, 50 mM
sodium acetate, pH 6.0, 10 mM EDTA, 1 mM benzamidine
hydrochloride, 1 mM phenylmethylsulfonyl ﬂuoride, 0.1 M
6-amino-n-hexanoic acid and 10 mM N-ethylmaleimide). HA
was puriﬁed from the extracts by centrifugation using a CsCl
gradient under both associative and dissociative conditions.
For the puriﬁcation of HA from the conditioned medium, the
medium was mixed with an equal volume of extraction buffer
concentrated two-fold, and then HA was puriﬁed by
centrifugation using a CsCl gradient under dissociative
conditions. A1D3 (400 mg) and D3 (2 mg) were digested with
0.8 mg/ml pronase at 37(C for 3 h, extracted with phenol/
chloroform, and barium acetate was added to make a ﬁnal
concentration of 0.25 M. Then ethanol was added to make
a 20% solution. The precipitate that was formed after
overnight refrigeration at 4(C was removed by centrifuga-
tion, and ethanol was added to the supernatant to make
a ﬁnal concentration of 40%. After leaving the preparation on
ice for 20 min, an HA precipitate was formed and collected
by centrifugation. The puriﬁed HA was separated by 0.8%
agarose gel electrophoresis and stained with Stains-All32.
Chondrocyte cultures were prepared from bovine meta-
tarsophalangeal joints as described previously33. After
plating the cells into 6-well plates precoated with type I
collagen at a ﬁnal concentration of 1.4! 106 cells/well, the
cells were cultured for 3 days in DMEM containing 10% fetal
calf serum, 100 units/ml of penicillin and 100 mg/ml of
streptomycin. Then, the cells were stimulated with 1 mM of
retinoic acid in serum-free medium containing 1 mg/ml HA
(1580 kDa), and the conditioned medium was collected
every 24 h. HA degradation products in the medium were
determined by electrophoresis through a 0.8% agarose gel.
To evaluate the effect of antioxidants on HA degradation,
superoxide dismutase (SOD; 100 units/ml), catalase (1000
units/ml), vitamin E (250 mM), and butylated hydroxytoluene
(BHT; 250 mM) were added on day 3. After 24 h of
cultivation, HA added into the medium was analyzed by
agarose gel electrophoresis.
INDUCTION OF ARTICULAR CARTILAGE DEGRADATION IN
RABBIT KNEE JOINT AND SAMPLING OF JOINT LAVAGE FLUID
Male Japanese white rabbits (body weight 1.50e1.99 kg)
were anesthetized by an intramuscular injection of a mixture
of 50 mg/ml ketamine and 20 mg/ml xylazine (2:1, v/v, 0.8 ml/
kg). Cartilage degradation was induced by an intra-articular
injection of 100 ng of human recombinant IL-1a in 0.5 ml of
phosphate buffered saline (PBS) containing 0.02% BSA into
the right knee. The vehicle was injected into the left knee. The
animals were sacriﬁced at 1, 2, 4, 8 or 24 h (nZ 3/time point)
by an intravenous injection of sodium pentobarbital. After
injecting 1 ml of PBS into each joint, the knee was ﬂexed 10
times, and lavage ﬂuid was collected from the synovial
cavity. The lavage ﬂuid was centrifuged and the supernatant
was analyzed by DMMB assay and immunoblotting.
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EFFECT OF AN MMP INHIBITOR, AG3340, ON THE
DEGRADATION OF TYPE II COLLAGEN AND AGGRECAN
IN A CARTILAGE EXPLANT CULTURE
AG3340 is a non-peptidic MMP inhibitor with Ki values of
30e300 pM against MMP-2, -3, -9, -13 and -1422. The
inhibitory activities of AG3340 were determined using
a ﬂuorometric assay with a quenched peptide substrate
for MMP-13 or a particle assay for aggrecanase-1 and
aggrecanase-2. AG3340 inhibited these proteinases in
a dose-dependent manner, and the concentrations of
AG3340, which gave 50% inhibition of MMP-13, aggreca-
nase-1 and aggrecanase-2 were 0.47G 0.06 nM,
130G 30 nM and 200G 38 nM, respectively (Table I).
More speciﬁcally, 2 mM of AG3340 inhibited 98% of
aggrecanase-1 and 91% of aggrecanase-2, respectively.
Oncostatin M is a proinﬂammatory cytokine of the IL-6
subfamily and is known to be a strong inducer of type II
collagen degradation in cartilage explant culture when in
combination with IL-1a34. Thus, bovine nasal cartilage was
stimulated with IL-1a and oncostatin M to induce type II
collagen degradation. Then, the release of hydroxyproline
into the culture medium was determined [Fig. 1(A)]. There
was no recognizable release of hydroxyproline into the
culture medium in the ﬁrst two weeks after stimulation. In
the third week, 93% of the initial hydroxyproline was
released. Since type II collagen in the cartilage was almost
completely degraded by the third week, the amount of
released hydroxyproline fell to basal levels in the fourth
week. Addition of AG3340 to the culture medium which was
stimulated with IL-1a and oncostatin M, produced a dose-
dependent reduction in the release of hydroxyproline. The
release was signiﬁcantly inhibited by 1 nM of AG3340, and
excess amounts of the compound (10 nM) completely
abolished the collagen degradation. The IC50 value for
collagen degradation was 0.78G 0.23 nM, which was close
to the value for the inhibition of MMP-13, 0.47G 0.06 nM
[Table I, Fig. 1(A)]. This similarity in IC50 values between the
organ culture system and the cell-free system indicated that
the effective concentration of AG3340 required to elicit an
inhibitory effect in the two systems was equivalent.
Retinoic acid was used to induce aggrecan degradation,
and then the degradation was quantiﬁed by the amount of
GAG released into the medium. The release of GAG was
induced on day 3 after stimulation, reaching a maximum on
day 4 [Fig. 1(B)]. Addition of AG3340 to the retinoic acid-
stimulated culture also inhibited GAG release in a dose-
dependent manner, and the calculated IC50 value of
AG3340 against the inhibition of GAG release was
7200G 1400 nM. AG3340 did not affect GAG release at
Table I
The IC50 values of AG3340 against MMP-13, aggrecanases, and
cartilage degradation in a cartilage explant culture system. The
activities of recombinant MMP-13 and aggrecanases were de-
termined as described in Materials and methods. The inhibitory
activities for the release of collagen or aggrecan (GAG) were
determined from the results described in Fig. 1(A) (in week 3) or
1(B) (on day 3), respectively.
IC50 (nM)
MMP-13 0.47G 0.06
Release of collagen in cartilage 0.78G 0.23
Aggrecanase-1 130G 32
Aggrecanase-2 200G 38
Release of aggrecan (GAG) in cartilage 7200G 1400a concentration of 1 mM. The release was not completely
inhibited even at the concentration of 10 mM of AG3340,
and the effect of AG3340 reached a plateau at 30 mM,
which was 150-fold the IC50 value for aggrecanase-1 and -
2. Considering that 30 mM of AG3340 was sufﬁcient for the
complete inhibition of MMP-13 and aggrecanases, these
results indicated that cartilage degradation was not solely
triggered by MMPs/aggrecanases in the cartilage culture
system.
RELEASE OF AGGRECAN G1 DOMAIN, LINK PROTEIN AND HA
INTO THE CULTURE MEDIUM UNDER STIMULATION WITH
RETINOIC ACID
For further characterization of the GAG release stimulated
by retinoic acid, a conditioned medium of bovine nasal
cartilage was harvested, and then the matrix components of
cartilage released into the medium were analyzed (Fig. 2).
Fig. 1. Effects of AG3340 on the degradation of type II collagen and
aggrecan in a cartilage explant culture. Type II collagen degrada-
tion in bovine nasal cartilage explant culture (A). The cartilage was
cultured with 10 ng/ml of IL-1a and 50 ng/ml of oncostatin M in the
presence of 0 (-), 1 (:) or 10 (;) nM of AG3340. The culture
media were changed weekly. Collagen degradation was de-
termined by the release of hydroxyproline into the medium from
the tissue. In the control experiment (C), cartilage was not
stimulated with IL-1a and oncostatin M. Aggrecan degradation in
the cartilage explant culture (B). Bovine nasal cartilage explants
were cultured with 1 mM of retinoic acid in the presence of 0 (-), 1
(:), 10 (;) or 30 (¤) mM of AG3340. The culture media were
collected every 24 h and degradation of aggrecan was measured by
the release of GAG into the medium. In the control experiment (C),
cartilage was not stimulated with retinoic acid.
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Fig. 2. Release of the G1 domain of aggrecan (A), link protein (B) and HA (C) into the medium of cartilage explant culture. Bovine nasal
cartilage was cultured in the presence or absence of 1 mM of retinoic acid. Aggrecan G1 domain generated by aggrecanases and link protein
were analyzed by immunoblotting using anti-NITEGE antiserum I19C, and an anti-link protein monoclonal antibody 8A4, respectively. HA in
the medium was determined using HA-test.As aggrecan interacts with HA, and the complex is stabilized
through the interaction of both molecules with link protein35,
the aggrecan G1 domain and link protein were expected to
be retained in the cartilage matrix even when cleaved by
MMPs/aggrecanases. However, immunoblotting analysis
with I19C antiserum speciﬁc to the aggrecanase-generated
neoepitope, NITEGE, showed that the retinoic acid stimuli
induced the release of the G1 domain of aggrecan, but the
G1 domain was not generated in the control culture
[Fig. 2(A)]. The release of the G1 domain was observed
on day 2, and reached maximum levels between days 3 and
5. It should be noted that no G1-containing fragment
generated by MMPs was detectable under the same
experimental conditions (data not shown). In addition to
the G1 domain, the link protein and HA were also observed
in the medium and their concentrations followed a similar
time course after stimulation with retinoic acid [Fig. 2(B, C)].
The released link protein and intact link protein puriﬁed from
cartilage had the same mobility in SDS-PAGE (data not
shown), suggesting that the link protein was not modiﬁed by
proteolytic enzymes. The release of the G1 domain and link
protein, and in particular that of HA, cannot be explained by
the actions of MMPs and/or aggrecanases. The experimentsusing AG3340 further provided evidence on the existence of
another degradation mechanism in cartilage. AG3340
inhibited only 20% of HA release at a concentration of
10 mM [Fig. 3(A)]. The release of link protein was not greatly
inhibited even in the presenceof 10 mMofAG3340 [Fig. 3(B)].
Immunoblotting analysis of the released aggrecan frag-
ments using an anti-G1 aggrecan antibody F12-1 showed
that retinoic acid induced the release of a major 70-kDa
fragment, G1-NITEGE373, and a minor 380-kDa fragment,
G1-TEPTVSQE1871, in the absence of AG3340 [Fig. 3(C)].
The former is a G1-containing fragment cleaved within the
IGD domain by aggrecanases, and proteolysis at another
aggrecanase site within the gap region generated the latter
fragment as analyzed by N-terminal protein sequencing in
our previous report23 [Fig. 3(D)]. AG3340 reduced the
amounts of the 70-kDa fragment in a dose-dependent
manner. In correlation with the decrease in the 70-kDa
fragment, the 380-kDa and other fragments with higher
molecular weights were accumulated in the medium. The
increase in these fragments reﬂects partial proteolysis by
aggrecanases. An excess amount of the inhibitor (10 mM),
markedly suppressed the appearance of the 70-kDa
fragment, and increased the amount of the 380-kDa and
1010 K. Sugimoto et al.: Cartilage degradation independent of MMP/aggrecanasesrelated fragments. All these G1-containing fragments should
be retained in the cartilage after cleavage by aggrecanases.
Furthermore, the release of intact aggrecan was detected in
the medium under the experimental conditions. The appear-
ance of intact aggrecan suggested that cartilage could be
degraded even in the absence of aggrecanases.
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Fig. 3. Effects of AG3340 on the release of matrix components.
Bovine nasal cartilage was treated with retinoic acid in the
presence of 1 mM or 10 mM of AG3340, and then the conditioned
medium was harvested on day 3. The concentration of HA in the
medium was determined using HA-test (A). After treatment with
chondroitinase and keratanase, the medium was analyzed by
immunoblotting with an anti-link protein monoclonal antibody, 8A4
(B), or an anti-aggrecan G1 monoclonal antibody, F12-1 (C). The
closed arrowhead, the open arrowhead, and the arrow represent
intact aggrecan, G1-TEPTVSQE (380 kDa), and G1-NITEGE
(70 kDa), respectively. Schematic representation of bovine aggre-
can fragments generated by aggrecanases (D).Aggrecan and link protein form a complex with HA in the
cartilage matrix as a proteoglycan aggregate4. Therefore,
the released matrix components were further analyzed by
size-exclusion chromatography. As reported by Sztrolovics
et al.36, they were released as an aggrecan ternary complex
(data not shown).
INVOLVEMENT OF HA DEGRADATION IN THE RELEASE
OF MATRIX COMPONENTS FROM CARTILAGE
To evaluate whether the release of the aggrecan ternary
complex into the culture medium was due to the degrada-
tion of HA, the molecular weight of HA retained in the
cartilage tissue or released into the culture media was
analyzed by agarose gel electrophoresis (Fig. 4). The
molecular weight of HA extracted from uncultured bovine
nasal cartilage was in the broad range of 100e500 kDa. In
contrast, HA from retinoic acid-treated cartilage was smaller
in size, and its molecular mass was approximately
40e60 kDa. Although a large chondroitin sulfate band
overlapped with that of HA, the released HA was found to
be degraded and its molecular mass of approximately
30e50 kDa could be determined. The contamination of
chondroitin sulfate was due to the difﬁculty in separating HA
from chondroitin sulfate. Treatment with pronase was used
to purify HA from the conditioned medium. The conditioned
medium contained a large amount of GAG-attaching
aggrecan backbone. The treatment by pronase led to the
contamination of chondroitin sulfate in the HA fractions.
In order to examine whether the degradation of HA was
mediated by the action(s) of chondrocytes, the degradation
activity of exogenously added HA was determined using
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Fig. 4. HA degradation in bovine nasal cartilage explant cultures.
Bovine nasal cartilage explants were cultured for 4 days with daily
medium change. Extracted HA from fresh cartilage, retinoic acid-
treated cartilage or retinoic acid-treated culture medium was
electrophoresed on 0.8% agarose gels and stained with Stains-
All. MK represents molecular weight markers which showed
a molecular mass of 800e1200 kDa and 40e60 kDa. The band
which appeared in the low molecular weight range in the retinoic
acid-treated culture medium was assigned to a contaminant,
chondroitin sulfate.
1011Osteoarthritis and Cartilage Vol. 12, No. 12Fig. 5. Hyaluronidase activity induced in a primary culture of chondrocytes. (A) Isolated bovine metacarpophalangeal chondrocytes were
stimulated by retinoic acid for 3 days, and then 1 mg/ml of HA (1580 kDa) was added into the culture in the presence of retinoic acid. In the
experiments using antioxidants, SOD (100 units/ml), catalase (1000 units/ml), vitamin E (250 mM) and BHT (250 mM) were each added with
HA on day 3. The mixture was incubated for 24 h. The medium was collected, electrophoresed on 0.8% agarose and stained with Stains-All.
(B) Incubation of HA with 1 mM of retinoic acid in the culture medium did not lead to degradation of HA.a monolayer culture of chondrocytes. Retinoic acid and HA
were added to the medium, and the cultures were
maintained with a daily medium exchange. Conditioned
media were collected, and the size of HA was analyzed by
agarose gel electrophoresis. Although the added HA was
not degraded in the control culture, HA in the culture
stimulated with retinoic acid was smaller in size on day 4,
indicating that the chondrocytes stimulated by retinoic acid
were responsible for the release of HA from the cartilage
[Fig. 5(A)]. As shown in Fig. 5(B), retinoic acid did not have
any direct effects on HA degradation. Free radicals
generated by chondrocytes could be considered to have
cleaved HA37,38. However, when the effects of antioxidants
on the HA degradation were determined by adding SOD,
catalase, vitamin E, and BHT, HA was still found to be
degraded (Fig. 5). Thus, the HA degradation was consid-
ered not to be mediated by free radicals such as reactive
oxygen species, but by chondrocyte-derived hyaluroni-
dase(s). It should also be noted that HA degradation was
not observed in the conditioned medium, which indicated
that the hyaluronidase was not released from the cells and
HA was directly cleaved by chondrocytes.
ACCUMULATION OF THE G1 DOMAIN OF AGGRECAN AND LINK
PROTEIN IN THE SYNOVIAL FLUID OF THE IL-1-INJECTED
RABBIT KNEE JOINT
The ﬁnding that the degradation of HA led to the release
of matrix components from cartilage, led us to examine
whether a similar cartilage degradation effect could be
observed in vivo. Cartilage degradation mediated by
hyaluronidase(s) was conﬁrmed using an acute arthritis
model [Fig. 6(A)]. Intra-articular injection of IL-1a resulted in
an increase of GAG released into the lavage ﬂuid at 8 and
24 h as compared with the vehicle control. Immunoblotting
analysis of the collected joint lavage ﬂuids with anti-G1
antibody showed that G1-containing aggrecan was re-
leased into the synovial ﬂuid, and the time course of the
release corresponded with that of GAG release [Fig. 6(B)].The detected aggrecan molecules containing the G1
domain had a size of 70 kDa, which is consistent with the
molecular mass of G1-NITEGE generated by the cleavage
with aggrecanases. Link protein was also released into the
synovial ﬂuid from cartilage after IL-1a injection, and the
time course of its release was similar to that of the released
GAG [Fig. 6(C)].
Discussion
Our present study demonstrated that cartilage was
degraded by a novel mechanism that was independent of
MMPs/aggrecanases. First, 30 mM of an MMP/aggrecanase
inhibitor, AG3340, only partially inhibited the GAG release
from cartilage explant cultures. At this concentration of
AG3340, collagenolytic activity in the explant culture and
enzymatic activities of MMP-13, aggrecanase-1 and ag-
grecanase-2 were completely inhibited. These results
demonstrate the existence of another mechanism of
cartilage degradation that is independent of the MMP/
aggrecanase pathway. Second, an aggrecan ternary
complex composed of the aggrecan G1 domain, link protein
and HA was released from cartilage under catabolic
conditions. Considering the fact that the G1 domain, link
protein and HA should be retained within the cartilage
matrix even after the actions of MMPs/aggrecanases35, the
release of these matrix components cannot be explained by
the action of MMPs/aggrecanases. The fact that the release
of the G1 domain, link protein and HA was not signiﬁcantly
inhibited by AG3340, and that the release of intact
aggrecan was observed in the treatment with a high
concentration of AG3340, reinforced our hypothesis of
there being another degradation pathway, which involves
enzymes other than MMPs/aggrecanases. Third, the re-
leased HA and extracted HA treated with retinoic acid were
reduced in size relative to that extracted from non-
stimulated cartilage. As the binding activities of the link
protein and aggrecan G1 domain to HA were still fully
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Fig. 6. Accumulation of the G1 domain of aggrecan and link protein in the synovial ﬂuid of the IL-1a-injected rabbit knee joint. (A) Rabbits were
injected intra-articularly with 100 ng IL-1a into the right knee (C) and the vehicle into the left knee (-). Then, the animals were necropsied at
indicated time points after injection. GAG released into the joint lavage was determined using a DMMB assay. (B, C) The collected joint lavage
samples were treated with chondroitinase and keratanase, and the reaction mixtures were analyzed by immunoblotting with an anti-aggrecan
G1 monoclonal antibody, F12-1 (B), or an anti-link protein monoclonal antibody, 8A4 (C). I and V represent IL-1a-treated and vehicle-treated
knees, respectively. The data shown are from two animals measured at the indicated time points (nZ 3).present, we concluded that the release of the complex was
due to the degradation of HA. Moreover, the fact that
hyaluronidase activities were induced in the primary
chondrocytes by retinoic acid also supports this conclusion.
It has been reported that free radicals such as reactive
oxygen species cleave HA37,38. However, the ineffective-
ness of antioxidants excludes the possibility of a non-
enzymatic degradation of HA by free radicals. HA is
retained in the matrix tissue through the interaction with
many molecules such as CD44 and type IX collagen39.
Once HA cleavage occurs, portions of HA that had no
anchoring to the matrix molecules were freed from the
matrix, and then released from the tissue. Thus, the release
of the aggrecan complex was concluded to be due to
hyaluronidase(s) derived from chondrocytes.
The hypothesis was further conﬁrmed in vivo using an
IL-1a-injected acute arthritis model. Intra-articular injection
of IL-1a resulted in the release of the G1 domain and link
protein in a manner similar to that of GAG, indicating that
hyaluronidase(s) also contributes to the GAG release in the
model of acute transient inﬂammation. Although the
release of the G1 domain and link protein in vivo was
presumed to be derived from HA degradation, we could not
detect any HA release from the cartilage in the model. A
large amount of HA in the synovial ﬂuid made it difﬁcult to
ascertain that the released HA was derived from cartilage
or synovial ﬂuid. Since the release of the G1 domain has
been reported in the synovial ﬂuids of OA and RA
patients40,41, the chondrocyte-derived hyaluronidase(s)may induce cartilage degradation under pathophysiological
conditions.
It is important to clarify how the function of hyaluroni-
dase(s) is differentiated from that of MMPs/aggrecanases in
cartilage degradation. In the present study, the majority of
the released G1-containing molecule was not intact
aggrecan, but G1-NITEGE fragments generated by aggre-
canases both in the bovine nasal cartilage culture and in the
acute arthritis model. Treatment with a high concentration of
the MMP inhibitor slightly inhibited the release of aggrecan,
link protein and HA, which showed the possibility that the
effect of aggrecanolysis widened the matrix space, and
facilitated the action of hyaluronidase(s) and vice versa. It is
likely that both pathways are functioning simultaneously,
and that these two mechanisms enhance the GAG release
in a cooperative manner. Recently, evidence on the release
of the G1 domain, link protein and HA from other cartilage
samples cultured in the presence of retinoic acid or IL-1b
has been reported36,42,43. In these studies, the response of
cartilage to stimulation with retinoic acid and IL-1b differed
depending on the type of cartilage being examined. In the
case of the treatment of bovine femoral epiphyseal cartilage
with retinoic acid, the release of GAG-containing products
was observed, but no evidence on the production of either
MMP- or aggrecanase-generated G1 domains was found42.
This observation suggests that HA degradation-dependent
GAG release is dominant in this culture system. The
preference for the dominance of one pathway may depend
on the tissue and the catabolic agents.
1013Osteoarthritis and Cartilage Vol. 12, No. 12Hyaluronidase(s) in cartilage or chondrocytes have not
been well characterized to date. Since the conditioned
medium did not show any activity, the enzymes appear to
be localized on the cell surface of chondrocytes. Although
the hyaluronidase(s) in the chondrocytes was presumed to
be active at neutral pH, no neutral hyaluronidase activity
was detected in the extracts from chondrocytes. There are
acid foci present on the cell surface where acidic
hyaluronidases may be activated. However, an up-regula-
tion of acidic hyaluronidases could not be identiﬁed under
the present experimental conditions. Chondrocytes pos-
sess lysosomal hyaluronidases44,45, and their high basal
acidic activities prevented the detection of any up-regulation
of acidic hyaluronidases on the cell surface. Six hyaluron-
idase-like sequences (PH-20, HYAL1, HYAL2, HYAL3,
HYAL4 and HYALP1) have been found in the human
genome46. PH-20, HYAL1, and HYAL2 have been reported
to possess hyaluronidase activities46,47, and HYAL1,
HYAL2 and HYAL3 are present in human chondro-
cytes44,45. On the other hand, bovine hyaluronidases have
been hardly characterized and only HYAL2 cDNA from
these six sequences has been cloned. Cloning and
characterization of these putative bovine hyaluronidases
are now in progress. CD44 has been reported to be
a receptor for HA and acts to facilitate the degradation of
HA by HYAL1 and HYAL246. Such molecules should also
be taken into account when considering cartilage degrada-
tion mediated by hyaluronidase(s). Further molecular
characterization of the pathway will provide new therapeutic
targets for cartilage diseases such as OA and RA.
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